Prospects for the use of fetal estrogen estetrol in endocrine gynecology


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Estrogens and gestagens have been used for hormonal contraception, treatment of gynecological diseases and pathological conditions in women for many decades. The use of these drugs may be associated with a number of rare but extremely adverse side effects, including an increased risk of venous and arterial thromboembolism, dyslipidemia and insulin resistance, and breast cancer; therefore, the development of new components of combined hormonal contraceptives and menopausal hormone therapy still remains a critical task. In recent years, clinical trials of new drugs containing the natural fetal estrogen estetrol have been conducted. It is believed that the new estrogenic component will reduce the adverse effects associated with taking estrogens and increase adherence to both hormonal contraception and menopausal hormone therapy for menopausal disorders. The purpose of this review is to assess the benefits and risks of using estetrol in endocrine gynecology

Texto integral

Acesso é fechado

Sobre autores

S. Apetov

Endocrine Health Center

Email: apetov@rambler.ru
Chelyabinsk, Russia

V. Apetova

Endocrine Health Center

Chelyabinsk, Russia

Bibliografia

  1. Holinka C.F, Diczfalusy E., Coeling Bennink H.J.T.C. Estetrol: A unique steroid in human pregnancy. J Steroid Biochem Mol Biol. 2008;110:138-43. doi: 10.1016/j.jsbmb.2008.03.027.
  2. Zucconi G, Lisboa B.P., Simonitsch E., et al. Isolation of 15-alpha-hydroxy-oestriol from pregnancy urine and from the urine of newborn infants. Acta Endocrinol (Copenh). 1967;56(3):413-23. doi: 10.1530/acta.0.0560413.
  3. Visser M, Coelingh Bennink H.J. Clinical applications for estetrol. J Steroid Biochem Mol Biol. 2009;114(1-2):85-9. Doi: 10.1016/j. jsbmb.2008.12.013.
  4. Benagiano G., Mancuso S., Mancuso F.P, et al. Studies on the metabolism of C-19 steroids in the human foeto-placental unit. 3. Dehydrogenation and reduction prducts formed by previable foetuses with androstenedione and testosterone. Acta Endocrinol (Copenh). 1968;57(2):187-207. doi: 10.1530/acta.0.0570187.
  5. Coelingh Bennink F., Holinka C.F., Visser M., et al. Maternal and fetal estetrol levels during pregnancy. Climacteric. 2008;11(Suppl 1):69- doi: 10.1080/13697130802056321.
  6. Tskitishvili E, Nisolle M., Munaut C., et al. Estetrol attenuates neonatal hypoxic-ischemic brain injury. Exp Neurol. 2014;261:298-307. doi: 10.1016/j.expneurol.2014.07.015.
  7. Visser M, Holinka C.F., Coelingh Bennink H.J. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric. 2008;11(Suppl 1:31-40. doi: 10.1080/13697130802056511.
  8. Coelingh Bennink H.J., Holinka C.F., Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11(Suppl 1):47-doi: 10.1080/13697130802073425.
  9. Coelingh Bennink H.J.T., Verhoeven C., Zimmerman Y, et al. Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women.Climacteric. 2017;20(3):285-89. doi: 10.1080/13697137.2017.1291608.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2022

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies